ScoreWhy is Panacea Biotec Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Net Sales has grown by an annual rate of 0.80% and Operating profit at -250.53% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.48
2
Flat results in Dec 25
- CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 81.61 cr
- NON-OPERATING INCOME(Q) is 61.29 % of Profit Before Tax (PBT)
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -20.86%, its profits have fallen by -139.9%
4
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
5
Underperformed the market in the last 1 year
- Even though the market (BSE500) has generated returns of 0.10% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -20.86% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Panacea Biotec for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Panacea Biotec
25.77%
-0.39
52.83%
Sensex
-4.95%
-0.49
12.94%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0.47%
EBIT Growth (5y)
-203.98%
EBIT to Interest (avg)
-13.79
Debt to EBITDA (avg)
2.73
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
0.72
Tax Ratio
2.85%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.56%
ROCE (avg)
-12.06%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
34
Price to Book Value
3.90
EV to EBIT
-85.04
EV to EBITDA
-688.37
EV to Capital Employed
4.09
EV to Sales
5.01
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.81%
ROE (Latest)
-2.31%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
PAT(Latest six months)
Higher at Rs 0.13 cr
NET SALES(Q)
Highest at Rs 166.75 cr
-1What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 64.37 cr
Loading Valuation Snapshot...
Here's what is working for Panacea Biotec
Profit After Tax (PAT) - Latest six months
Higher at Rs 0.13 cr
than preceding 12 month period ended Mar 2026 of Rs -47.25 crMOJO Watch
In the half year the company has already crossed PAT of the previous twelve months
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 166.75 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 166.75 cr has Grown at 25.82%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Here's what is not working for Panacea Biotec
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 64.37 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
